It was shown that the introduction of IDH mutant or treatment with the oncometabolite R-2-HG resulted in reduced levels of a chemokine CXCL10 and its regulator STAT1 in the syngeneic mouse glioma models. The gene discussed is IDH1; the disease is glioma.